this one has just come to attention from another site, has anyone any views good/bad before i plunge in with a long term view

RNS Number:5210R
Deltex Medical Group PLC
31 October 2003

Deltex Medical Group plc ("Deltex Medical" or the "Company")
Director Shareholdings

Deltex Medical announced on 28 October 2003, that it has placed 5,609,269 new
ordinary shares at 15p per share with various institutional and other investors and certain of the Directors, raising approximately #840,000 before expenses.



The following Directors have participated as investors in the placing and their interests in the Company's total enlarged issued ordinary share capital
following the placing are as follows:

Following the placing
Name of Director Number of placing shares Holding of shares % of issued share capital acquired

Nigel Keen 133,333 3,585,577(1) 5.81
Ewan Phillips 100,000 465,714 0.75
George Flouty 30,000 164,285 0.27
Peter Smedvig 280,000 944,478(2) 1.53
Edwin Snape - 2,879,925 4.67
Andy Hill - 42,857 0.07
Daniel Bretonneau - 142,857 0.23

(1) includes 589,700 shares held as trustee and executor of Pauline
Thomas Charity Will Trust

(2) includes shares held as director of Peder Smedvig Capital AS

The #81,500 invested by the Directors is in addition to the total amount of
#371,780 subscribed by the Directors as part of the #1.32 million placing before expenses announced on 7 May 2003.

Following the placing, the aggregate interest of all the Directors' interests in the shares of the Company totals 8,225,693 ordinary shares representing 13.33% of the issued share capital.

31 October 2003



The comapny, Deltex Medical primarily develops, assembles and markets a cardiac function monitor and therapy guidance device, the CardioQ ("CardioQ"/"Monitor"). The CardioQ incorporates the Company's proprietary software and a narrow, easy-to-use, minimally invasive, disposable oesophageal probe,used for transmitting and receiving an ultra-sound ("Doppler") signal. By using this Doppler technology, the CardioQ provides clinicians with an early warning on the haemodynamic condition of critically ill patients. This continuous, real-time monitoring facilitates the administration of fluids or drugs in a timely fashion and provides an immediate assessment of their impact.

There are now over 800 CardioQs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 75 clinical publications on the use of the CardioQ which have repeatedly:-

* validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works

* proved that the CardioQ works over a variety of types of operation

* shown that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients.

The Company is also currently developing a number of new products:-

* the SupraQ - a monitor based on the CardioQ technology but using a completely non-invasive probe; the prototype is being prepared for clinical testing

* the NeuroQ - a monitor designed to measure blood flow in the brain; the new prototype is in preparation for clinical trials.

Deltex Medical believes the potential worldwide market for the CardioQ and its accompanying probes exceeds #1 billion per annum.

Nigel Keen, Deltex Medical's Chairman, commented:

"The year to 31 December 2002 was one of substantial achievement for Deltex Medical. We have passed a large number of significant milestones both in establishing an extremely strong base for our UK business and in focusing our activities on those markets where we can expect early returns from our
investment. In addition we have introduced an exciting new range of disposable products which allow clinicians lower cost access to our technology and we have expanded our manufacturing capacity to allow us to meet the demand for our disposable products which we are seeing from the markets which we serve.

Just bought in, lots of positive vibes on this stock, just have to wait and seen now...